Skip to Content
Global News Select

GlaxoSmithKline 2Q Net Profit Fell Despite Higher Sales; Backs 2021 Outlook — Update

By Cecilia Butini

 

GlaxoSmithKline PLC said Wednesday that second-quarter net profit fell from the previous year, though sales grew, and backed its outlook for the full year.

The British pharmaceutical major posted net profit of 1.40 billion pounds ($1.94 billion) for the period, down from GBP2.26 billion the year prior. Adjusted earnings per share were 28.1 pence compared with 19.2 pence for the same period a year earlier.

Sales came in at GBP8.09 billion, up from GBP7.62 billion for the second quarter of 2020, when both pharmaceuticals and vaccine sales were affected by the coronavirus pandemic.

Pharmaceuticals sales rose 3%, driven by growth in new products and specialty products and as a result of favorable comparables with the previous year, which was hit by destocking following pent-up demand in the first quarter, the company said.

Vaccine turnover grew 39% on year, GlaxoSmithKline said. However, the company said that its performance continued to be hurt by lower demand for routine adult vaccination due to Covid-19 vaccination programs taking priority. GlaxoSmithKline said it expects vaccine revenue for 2021 to be broadly flat.

The company backed a previously given outlook for 2021, saying that it expects adjusted EPS to decline by mid-to-high single-digit percentage at constant exchange rates. Regarding 2022, it said it expects meaningful improvements in revenues and margins.

GlaxoSmithKline declared a dividend of 19 pence a share for the second quarter and said it continues to expect a dividend of 80 pence a share for the full year 2021.

The company said it expects sales of its solutions for Covid-19, including vaccine adjuvants and monoclonal-antibody treatment sotrovimab, to contribute approximately between 4% and 6% to full-year adjusted EPS growth.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

July 28, 2021 08:37 ET (12:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.